How much funding has CG Oncology raised?

CG Oncology has raised $317.6M in total funding, most recently a Series F round.

Who are CG Oncology's investors?

CG Oncology's investors include TCG Crossover, ORI Capital, Longitude Capital, WI Harper Group, Ally Bridge Group, RA Capital Management.

When was CG Oncology founded?

CG Oncology was founded in 2010.

Where is CG Oncology headquartered?

CG Oncology is headquartered in Irvine, California, United States.

What industry is CG Oncology in?

CG Oncology operates in Biotech, Healthcare.

How many employees does CG Oncology have?

CG Oncology has 51-200 employees.

CG Oncology

IPO

Focused on the Future of Bladder Cancer

Public · Irvine, United States · Founded 2010 · $317.6M raised

Biotech

Healthcare

Headquarters: Irvine, California
Employees: 51–200
Founded: 2010
Business Model: B2B
Website: cgoncology.com

Total Funding: $317.6M
Last Round: $105.0M Series FAug 2023
Rounds: 6
Type: Public

About

CG Oncology (formerly Cold Genesys) is a late-stage clinical biopharmaceutical company focused on developing and commercializing bladder-sparing immunotherapies. Its lead product candidate, cretostimogene grenadenorepvec, is an investigational engineered oncolytic immunotherapy (OIT) for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). Founded in 2010, the company completed its IPO on Nasdaq in January 2024. CG Oncology's vision is a world where urologic cancer patients benefit from innovative immunotherapies that allow them to live with dignity and enhanced quality of life.

Summary

CG Oncology is a Biotech company based in Irvine, United States, founded in 2010. It has raised $317.6M in total across 6 rounds, most recently a $105.0M Series F round in Aug 2023. Investors include TCG Crossover, ORI Capital and Longitude Capital.

LinkedIn X (Twitter)